A carregar...
Remarkable response with pembrolizumab plus albumin-bound paclitaxel in 2 cases of HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy
In clinical practice, one subgroup patients of breast cancer might have developed resistance to multi-anti-HER2 targeted drugs(trastuzumab, lapatinib and/or T-DM1) and can not benefit from the anti-HER2 targeted therapy continuously. We attempt to change the next therapic way for these patients. Two...
Na minha lista:
| Publicado no: | Cancer Biol Ther |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5902233/ https://ncbi.nlm.nih.gov/pubmed/29333945 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2017.1414761 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|